Alentis Therapeutics

Biopharma financing during the fourth quarter of 2024 totaled $16.8bn from 251 deals. Of those, 60 reached $100m or more. The follow-on public offering (FOPO) and venture financing categories tied for

Venture capital fundraising by biopharmaceutical companies rose to $7.11bn in the fourth quarter of 2024, after falling to $6.46bn in Q3 from $7.95bn in Q2, according to data from Evaluate. But the ye

Alentis Therapeutics has raised $181.4m in a series D round to help progress its potential first-in-class Claudin-1 positive (CLDN1+) antibodies and antibody-drug conjugates (ADCs). While another cla

TRex Bio Inc. (TRexBio) announced an $84m series B venture capital round on 13 November that it will use to develop lead drug candidate TRB-061, a TNFR2 agonist, through early clinical proof-of-concep